Concepedia

Kari R. Nations

KR

Statistics

Publications

7

Citations

255

H-Index

7

Active since

2011

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (Netherlands)

The University of Texas at San Antonio Health Science Center

Kari R. Nations is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in psychopharmacology, pharmacology, and medicine.

Publications per year

2011–2014

7

Publications

7

Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial

Kari R. Nations, Peter Dogterom, Roberta Bursi et al. · Journal of Psychopharmacology · 2012 · 71 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

Armin Szegedi, Jun Zhao, Arjen van Willigenburg et al. · BMC Psychiatry · 2011 · 62 citations · Full text

Pharmacy, Pharmacology, Psychiatry +17

Efficacy and Safety of the Glycine Transporter‐1 Inhibitor Org 25935 for the Prevention of Relapse in Alcohol‐Dependent Patients: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Andrea de Bejczy, Kari R. Nations, Armin Szegedi et al. · Alcoholism Clinical and Experimental Research · 2014 · 32 citations

Medicine, Pharmacology, Psychiatry +17

Obtained effect size as a function of sample size in approved antidepressants

Michael Gibertini, Kari R. Nations, John A. Whitaker · International Clinical Psychopharmacology · 2012 · 27 citations

Medicine, Pharmacology, Psychiatry +16

Evaluation of the Glycine Transporter Inhibitor Org 25935 as Augmentation to Cognitive-Behavioral Therapy for Panic Disorder

Kari R. Nations, Jasper A. J. Smits, David F. Tolin et al. · The Journal of Clinical Psychiatry · 2012 · 23 citations

Medicine, Pharmacotherapy, Psychiatry +17

1–5 of 7